Posted by Site Administrator on December 6, 2012
“These results support the importance of the immune system, and more specifically T-reg populations, in modulating the clinical course of a patient’s disease,” Appel said. “Thus, enhancing the number of T-regs and their anti-inflammatory functions in ALS patients could have important therapeutic benefits in slowing the rate of disease progression and stabilizing ALS patients for longer periods of time than currently available therapies.”
Categories: Research News, Treatments
| 
Tags: ALS, ALS community, ALS diagnostics, ALS progression, ALS research, ALS TDI Webinar: TDI 132, ALS treatments, amyotrophic lateral sclerosis, Bob Stehlin, California Pacific Medical Center, EMBO Molecular Medicine, FOXP3, FOXP3 protein, Immune system cells, Immunomodulator CTLA4-FC Being Tested in ALS Mouse Model, Lou Gehrig's disease, Methodist Neurological Institute, PALS, Phase 2 Clinical Trial for NP001 Shows Possible Benefit, RASCALS Foundation, regulatory T cells, Robert A. Stehlin Campaign for ALS, St.Louis RASCALS ALS Lou Gehrig's Disease amotrophic lateral sclerosis, Stan Appel, T-regs
| 
No comments
Posted by Site Administrator on November 6, 2012
Some 27 percent of patients receiving the higher dose had no progression of the disease, about 2.5 times as many as were seen in a placebo group, a post-hoc analysis showed.
Categories: Research News, Treatments
| Tags: ALS community, ALS cure, ALS medical care, ALS research, ALS slowing progression, ALS treatments, amyotrophic lateral sclerosis, Biogen Idec, Bob Stehlin, California Pacific Medical Center, Dr. Robert Miller, Neuraltus CEO John Walker, Neuraltus Pharmaceuticals, NP-001, PALS, Phase III, RASCALS Foundation, St.Louis RASCALS ALS Lou Gehrig's Disease amotrophic lateral sclerosis
| No comments
Posted by Site Administrator on January 9, 2012
Results of the first stage showed that receiving dexpramipexole appeared to slow the progression of symptoms measured both by the ALS Functional Rating Scale and by pulmonary capacity. The second stage had similar results, with slower disease progression and a reduced risk of death in participants receiving the higher dosage.
Categories: Research News
| Tags: ALS, ALS community, amyotrophic lateral sclerosis, Biogen Idec, California Pacific Medical Center, Columbia University Medical Center, Craig Amburgey, Dan Moore, David Schoenfeld, dexpramipexole, Donald Archibald, Evan Ingersoll, Hiroshi Mitsumoto, James Mather, Jeremy Shefner, Juliet Moritz, Knopp Biosciences, Lou Gehrig's disease, Mary Sullivan, Massachusetts General Hospital, Massachusetts General Hospital (MGH) Neurology Clinical Trials Unit and ALS Center, Merit Cudkowicz MD, MGH Biostatistics, Michael Bozik, Mitochondrial dysfunction, neurodegenerative disease, Northeast ALS Consortium, Nuedexta, RASCALS Foundation, riluzole, Robert A. Stehlin Campaign for ALS, Robert Miller, State University of New York Upstate Medical University Syracuse, Valentin Gribkoff PhD
| No comments
